Actinogen Medical - Refining the upcoming XanaMIA Phase IIb study
Actinogen intends to start patient enrolment and dosing in H2 CY23 in the Phase IIb XanaMIA study portion assessing Xanamem in lead indication...
313 Views
Actinogen Medical - Continued focus on Xanamem
Actinogen’s Q323 update reiterated the company’s focus on advancing its lead asset Xanamem. Patient recruitment in the Phase IIa XanaCIDD study in...
125 Views
Actinogen Medical - Getting ready for the next Alzheimer’s study
Actinogen is on track to start US recruitment in Q2 CY23 for the six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study...
220 Views
Actinogen Medical - On track to start Phase IIb XanaMIA study
Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month,...
223 Views
Actinogen Medical - XanaMIA clears hurdle to start US recruitment
Actinogen has announced that the US FDA has provided the required approvals for it to proceed with US recruitment for its planned six-month,...
670 Views